Trade Landos Biopharma, Inc. - LABP CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.09 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026346% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004124% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Landos Biopharma Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 4.18 |
Open* | 4.08 |
1-Year Change* | 946.15% |
Day's Range* | 4.08 - 4.27 |
52 wk Range | 0.21-1.37 |
Average Volume (10 days) | 72.96K |
Average Volume (3 months) | 3.98M |
Market Cap | 9.67M |
P/E Ratio | -100.00K |
Shares Outstanding | 31.17M |
Revenue | N/A |
EPS | -0.70 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | Aug 9, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 4, 2023 | 4.18 | 0.03 | 0.72% | 4.15 | 4.25 | 4.01 |
Dec 1, 2023 | 4.12 | 0.02 | 0.49% | 4.10 | 4.12 | 4.00 |
Nov 30, 2023 | 4.10 | 0.18 | 4.59% | 3.92 | 4.15 | 3.92 |
Nov 29, 2023 | 4.08 | -0.40 | -8.93% | 4.48 | 4.48 | 4.03 |
Nov 28, 2023 | 4.46 | 0.10 | 2.29% | 4.36 | 4.46 | 4.36 |
Nov 27, 2023 | 4.13 | 0.00 | 0.00% | 4.13 | 4.41 | 4.13 |
Nov 24, 2023 | 4.55 | 0.15 | 3.41% | 4.40 | 4.75 | 4.40 |
Nov 22, 2023 | 4.33 | 0.53 | 13.95% | 3.80 | 4.33 | 3.80 |
Nov 21, 2023 | 4.27 | 0.13 | 3.14% | 4.14 | 4.38 | 4.14 |
Nov 20, 2023 | 3.73 | -0.15 | -3.87% | 3.88 | 3.88 | 3.73 |
Nov 17, 2023 | 4.03 | -0.01 | -0.25% | 4.04 | 4.10 | 3.91 |
Nov 16, 2023 | 3.94 | 0.08 | 2.07% | 3.86 | 4.20 | 3.78 |
Nov 15, 2023 | 3.93 | 0.16 | 4.24% | 3.77 | 3.93 | 3.77 |
Nov 14, 2023 | 3.93 | 0.05 | 1.29% | 3.88 | 3.94 | 3.88 |
Nov 13, 2023 | 3.75 | 0.14 | 3.88% | 3.61 | 3.79 | 3.61 |
Nov 10, 2023 | 3.29 | -0.59 | -15.21% | 3.88 | 3.88 | 3.29 |
Nov 9, 2023 | 3.88 | -0.22 | -5.37% | 4.10 | 4.10 | 3.88 |
Nov 8, 2023 | 4.12 | 0.03 | 0.73% | 4.09 | 4.12 | 4.00 |
Nov 7, 2023 | 4.09 | 0.13 | 3.28% | 3.96 | 4.14 | 3.95 |
Nov 6, 2023 | 3.88 | -0.13 | -3.24% | 4.01 | 4.05 | 3.83 |
Landos Biopharma, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, March 21, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q4 2023 Landos Biopharma Inc Earnings Release Q4 2023 Landos Biopharma Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 18 | 0 | 0 | 0 |
Total Operating Expense | 40.561 | 56.816 | 30.676 | 13.29 | 7.939 |
Selling/General/Admin. Expenses, Total | 14.581 | 15.252 | 5.338 | 1.478 | 1.136 |
Research & Development | 25.68 | 41.564 | 25.338 | 11.812 | 6.803 |
Operating Income | -40.561 | -38.816 | -30.676 | -13.29 | -7.939 |
Interest Income (Expense), Net Non-Operating | 0.026 | -0.018 | 0.077 | -0.337 | -0.11 |
Other, Net | 1.259 | 0.412 | 0.455 | 0.16 | 2.005 |
Net Income Before Taxes | -39.276 | -38.422 | -30.144 | -13.467 | -6.044 |
Net Income After Taxes | -39.276 | -38.422 | -30.144 | -13.467 | -6.044 |
Net Income Before Extra. Items | -39.276 | -38.422 | -30.144 | -13.467 | -6.044 |
Net Income | -39.276 | -38.422 | -30.144 | -13.467 | -6.044 |
Income Available to Common Excl. Extra. Items | -39.276 | -38.422 | -30.144 | -13.467 | -6.044 |
Income Available to Common Incl. Extra. Items | -39.276 | -38.422 | -30.144 | -13.467 | -6.044 |
Diluted Net Income | -39.276 | -38.422 | -30.144 | -13.467 | -6.044 |
Diluted Weighted Average Shares | 40.2549 | 37.5585 | 40.1176 | 39.1632 | 39.1632 |
Diluted EPS Excluding Extraordinary Items | -0.97568 | -1.02299 | -0.75139 | -0.34387 | -0.15433 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
Diluted Normalized EPS | -0.96823 | -1.02299 | -0.75139 | -0.34387 | -0.15433 |
Revenue | 0 | 18 | |||
Unusual Expense (Income) | 0.3 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 6.479 | 6.513 | 7.829 | 11.266 | 14.953 |
Selling/General/Admin. Expenses, Total | 3.153 | 3.099 | 2.967 | 4.662 | 3.853 |
Research & Development | 3.326 | 3.414 | 4.862 | 6.604 | 10.8 |
Operating Income | -6.479 | -6.513 | -7.829 | -11.266 | -14.953 |
Interest Income (Expense), Net Non-Operating | -0.004 | 0 | 0 | 0.025 | 0.001 |
Other, Net | 0.449 | 1.281 | -0.067 | -0.043 | 0.088 |
Net Income Before Taxes | -6.034 | -5.232 | -7.896 | -11.284 | -14.864 |
Net Income After Taxes | -6.034 | -5.232 | -7.896 | -11.284 | -14.864 |
Net Income Before Extra. Items | -6.034 | -5.232 | -7.896 | -11.284 | -14.864 |
Net Income | -6.034 | -5.232 | -7.896 | -11.284 | -14.864 |
Income Available to Common Excl. Extra. Items | -6.034 | -5.232 | -7.896 | -11.284 | -14.864 |
Income Available to Common Incl. Extra. Items | -6.034 | -5.232 | -7.896 | -11.284 | -14.864 |
Diluted Net Income | -6.034 | -5.232 | -7.896 | -11.284 | -14.864 |
Diluted Weighted Average Shares | 64.8423 | 40.2549 | 40.2549 | 40.2549 | 40.2549 |
Diluted EPS Excluding Extraordinary Items | -0.09306 | -0.12997 | -0.19615 | -0.28031 | -0.36925 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.09306 | -0.12997 | -0.19615 | -0.28031 | -0.36179 |
Revenue | 0 | 0 | 0 | ||
Unusual Expense (Income) | 0 | 0 | 0 | 0.3 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 45.253 | 92.146 | 29.888 | 50.11 | 2.492 |
Cash and Short Term Investments | 44.402 | 90.88 | 28.134 | 49.965 | 0.359 |
Cash & Equivalents | 36.64 | 8.305 | 2.416 | 9.808 | 0.359 |
Short Term Investments | 7.762 | 82.575 | 25.718 | 40.157 | 0 |
Total Receivables, Net | 0.154 | 0.001 | 2.092 | ||
Prepaid Expenses | 0.851 | 1.266 | 0.202 | 0.144 | 0.041 |
Total Assets | 45.253 | 92.879 | 30.332 | 50.48 | 2.796 |
Property/Plant/Equipment, Total - Net | 0 | 0.707 | 0.444 | 0.359 | 0.304 |
Property/Plant/Equipment, Total - Gross | 0.166 | 1.248 | 0.793 | 0.571 | 0.413 |
Accumulated Depreciation, Total | -0.166 | -0.541 | -0.349 | -0.212 | -0.109 |
Other Long Term Assets, Total | 0 | 0.026 | 0 | 0.011 | 0 |
Total Current Liabilities | 6.122 | 16.611 | 11.034 | 3.026 | 1.796 |
Accounts Payable | 3.435 | 12.908 | 8.606 | 2.048 | 1.692 |
Accrued Expenses | 2.687 | 3.703 | 1.939 | 0.978 | 0.104 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6.122 | 16.611 | 11.31 | 3.026 | 1.796 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 39.131 | 76.268 | 19.022 | 47.454 | 1 |
Redeemable Preferred Stock | 0 | 0 | 73.037 | 73.037 | 0.032 |
Common Stock | 0.403 | 0.403 | 0.071 | 0.063 | 0.059 |
Additional Paid-In Capital | 172.212 | 170.241 | 1.633 | 0.016 | 10.044 |
Retained Earnings (Accumulated Deficit) | -133.427 | -94.151 | -55.729 | -25.585 | -9.135 |
Other Equity, Total | -0.057 | -0.225 | 0.01 | -0.077 | 0 |
Total Liabilities & Shareholders’ Equity | 45.253 | 92.879 | 30.332 | 50.48 | 2.796 |
Total Common Shares Outstanding | 40.2549 | 40.2549 | 40.1176 | 39.1632 | 39.1632 |
Other Current Assets, Total | 0 | 1.398 | |||
Other Current Liabilities, Total | 0 | 0.489 | |||
Other Liabilities, Total | 0 | 0.276 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 51.184 | 45.253 | 49.488 | 58.038 | 77.359 |
Cash and Short Term Investments | 50.006 | 44.402 | 47.991 | 55.751 | 73.796 |
Cash & Equivalents | 45.244 | 36.64 | 28.88 | 19.241 | 11.288 |
Short Term Investments | 4.762 | 7.762 | 19.111 | 36.51 | 62.508 |
Total Receivables, Net | |||||
Prepaid Expenses | 1.178 | 0.851 | 1.497 | 2.287 | 3.563 |
Other Current Assets, Total | |||||
Total Assets | 51.184 | 45.253 | 49.488 | 58.038 | 77.61 |
Property/Plant/Equipment, Total - Net | 0 | 0 | 0 | 0.251 | |
Total Current Liabilities | 4.16 | 6.122 | 5.475 | 6.51 | 15.507 |
Accounts Payable | 2.298 | 3.435 | 3.204 | 4.711 | 9.803 |
Accrued Expenses | 1.862 | 2.687 | 2.271 | 1.799 | 5.704 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | |||||
Total Liabilities | 4.16 | 6.122 | 5.475 | 6.51 | 15.507 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | |||||
Total Equity | 47.024 | 39.131 | 44.013 | 51.528 | 62.103 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
Common Stock | 0.312 | 0.403 | 0.403 | 0.403 | 0.403 |
Additional Paid-In Capital | 186.094 | 172.212 | 172.016 | 171.816 | 171.182 |
Retained Earnings (Accumulated Deficit) | -139.461 | -133.427 | -128.195 | -120.299 | -109.015 |
Other Equity, Total | 0.079 | -0.057 | -0.211 | -0.392 | -0.467 |
Total Liabilities & Shareholders’ Equity | 51.184 | 45.253 | 49.488 | 58.038 | 77.61 |
Total Common Shares Outstanding | 31.1684 | 40.2549 | 40.2549 | 40.2549 | 40.2549 |
Other Long Term Assets, Total | 0 | 0 | 0 | ||
Property/Plant/Equipment, Total - Gross | 0.166 | 0.575 | 1.041 | 1.125 | |
Accumulated Depreciation, Total | -0.166 | -0.575 | -1.041 | -0.874 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -39.276 | -38.422 | -30.144 | -13.467 | -6.044 |
Cash From Operating Activities | -45.771 | -27.061 | -22.962 | -9.874 | -6.896 |
Cash From Operating Activities | 0.577 | 0.196 | 0.137 | 0.103 | 0.08 |
Non-Cash Items | 3.002 | 5.274 | 1.174 | 0.213 | 0.369 |
Cash Interest Paid | 0 | 0.027 | 0.004 | ||
Changes in Working Capital | -10.074 | 5.891 | 5.871 | 3.277 | -1.301 |
Cash From Investing Activities | 74.06 | -58.706 | 14.131 | -40.325 | -0.043 |
Capital Expenditures | -0.007 | -0.44 | -0.181 | -0.158 | -0.043 |
Other Investing Cash Flow Items, Total | 74.067 | -58.266 | 14.312 | -40.167 | 0 |
Cash From Financing Activities | 0 | 91.607 | 1.518 | 59.648 | 5 |
Issuance (Retirement) of Stock, Net | 0 | 93.514 | 1.518 | 51.668 | 5 |
Issuance (Retirement) of Debt, Net | 0 | 7.98 | 0 | ||
Net Change in Cash | 28.335 | 5.889 | -7.392 | 9.449 | -1.939 |
Foreign Exchange Effects | 0.046 | 0.049 | -0.079 | ||
Financing Cash Flow Items | 0 | -1.907 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -6.034 | -39.276 | -34.044 | -26.148 | -14.864 |
Cash From Operating Activities | -8.17 | -45.771 | -42.072 | -34.499 | -16.502 |
Cash From Operating Activities | 0 | 0.577 | 0.577 | 0.577 | 0.353 |
Non-Cash Items | 0.256 | 3.002 | 2.82 | 2.238 | 1.381 |
Changes in Working Capital | -2.392 | -10.074 | -11.425 | -11.166 | -3.372 |
Cash From Investing Activities | 3.104 | 74.06 | 62.589 | 45.377 | 19.506 |
Capital Expenditures | 0 | -0.007 | -0.007 | -0.007 | -0.007 |
Other Investing Cash Flow Items, Total | 3.104 | 74.067 | 62.596 | 45.384 | 19.513 |
Cash From Financing Activities | 13.666 | 0 | 0 | 0 | 0 |
Issuance (Retirement) of Stock, Net | 13.666 | 0 | 0 | 0 | 0 |
Net Change in Cash | 8.604 | 28.335 | 20.575 | 10.936 | 2.983 |
Foreign Exchange Effects | 0.004 | 0.046 | 0.058 | 0.058 | -0.021 |
Financing Cash Flow Items | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Landos Biopharma, Inc. Company profile
About Landos Biopharma Inc
Landos Biopharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. The Company through its artificial intelligence (AI)-based precision medicine platform, LANCE platform, identifies therapeutic targets based on predictions of immunometabolic function and create therapeutic candidates to engage those targets in areas of unmet medical need. Its platform discovers small molecule therapeutics for patients with autoimmune diseases that targets mechanisms of action, including LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. It identifies novel immunometabolic targets and product candidates across indications, such as ulcerative colitis (UC), Crohn’s disease (CD), eosinophilic esophagitis (EoE), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its Omilancor is an oral, gut restricted LANCL2 agonist in development for the treatment of UC, CD and EoE.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Landos Biopharma Inc revenues increased from $0K to $18M. Net loss decreased 3% to $18.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.48 to -$0.57.
Industry: | Biotechnology & Medical Research (NEC) |
1800 Kraft Drive, Suite 216
24060
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com